<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05044195</url>
  </required_header>
  <id_info>
    <org_study_id>V118_23</org_study_id>
    <nct_id>NCT05044195</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age</brief_title>
  <official_title>A Phase 3, Randomized, Observer-blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine in Comparison With a Licensed Quadrivalent Influenza Vaccine, in Adults 50 to 64 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seqirus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seqirus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 3 study is a randomized, observer-blind study of aQIV (an MF59-adjuvanted&#xD;
      quadrivalent influenza vaccine) compared with a licensed quadrivalent influenza vaccine in&#xD;
      adults 50 to 64 years of age. The aim of the study is to demonstrate a noninferior immune&#xD;
      response for aQIV versus the comparator vaccine for all four vaccine strains, and a superior&#xD;
      immune response for at least two of the four vaccine strains.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2021</start_date>
  <completion_date type="Anticipated">May 9, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 9, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity Endpoint: Geometric mean titer (GMT) and GMT ratio of hemagglutination inhibition (HI) antibodies at Day 22 for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria vaccine strains</measure>
    <time_frame>Day 22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity Endpoint: Seroconversion rate (SCR) and SCR difference for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria vaccine strains</measure>
    <time_frame>Day 1 to Day 22</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: GMT and GMT ratio of HI antibodies at Day 22 for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria vaccine strains</measure>
    <time_frame>Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: GMT and GMT ratio of HI antibodies at Day 181 for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria vaccine strains</measure>
    <time_frame>Day 181</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: GMT and GMT ratio of HI antibodies at Day 271 for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria vaccine strains</measure>
    <time_frame>Day 271</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: GMT of HI antibodies on Day 1, Day 22, Day 181, and Day 271 for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria vaccine strains</measure>
    <time_frame>Day 1 to Day 271</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: Geometric mean fold increase (GMFI) for Day 22/Day 1, Day 181/Day 1, and Day 271/Day 1 for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria vaccine strains</measure>
    <time_frame>Day 1 to Day 271</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: The percentage of subjects with a titer ≥1:40 at Day 1, Day 22, Day 181, and Day 271 for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria vaccine strains</measure>
    <time_frame>Day 1 to Day 271</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: SCR at Day 22, Day 181, and Day 271 for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria vaccine strains</measure>
    <time_frame>Day 1 to Day 271</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint: Solicited local and systemic AEs for 7 days following vaccination</measure>
    <time_frame>Day 1 through Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint: All unsolicited AEs for 21 days following vaccination</measure>
    <time_frame>Day 1 through Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint: Serious adverse events (SAEs), adverse events (AEs) leading to withdrawal from the study, and Adverse Events of Special Interest (AESIs)</measure>
    <time_frame>Day 1 through Day 271</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2018</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>aQIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjuvanted QIV containing 2 influenza type A strains and 2 influenza type B strains</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator QIV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non-adjuvanted comparator QIV containing 2 influenza type A strains and 2 influenza type B strains</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aQIV</intervention_name>
    <description>Participants receive a 0.5-mL intramuscular dose of aQIV on Day 1</description>
    <arm_group_label>aQIV</arm_group_label>
    <other_name>Fluad Tetra/Quadrivalent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator QIV</intervention_name>
    <description>Participants receive a 0.5-mL intramuscular dose of Comparator QIV on Day 1</description>
    <arm_group_label>Comparator QIV</arm_group_label>
    <other_name>Fluarix Tetra/Quadrivalent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        In order to participate in this study, all subjects must meet ALL of the following&#xD;
        inclusion criteria:&#xD;
&#xD;
          -  Individuals 50 through 64 years of age on the day of informed consent&#xD;
&#xD;
          -  Individuals who have voluntarily given written consent after the nature of the study&#xD;
             has been explained according to local regulatory requirements, prior to study entry&#xD;
&#xD;
          -  Individuals who can comply with study procedures including follow-up&#xD;
&#xD;
          -  Males, females of non-childbearing potential or females of childbearing potential who&#xD;
             are using an effective birth control method, at least 30 days prior to informed&#xD;
             consent, which they intend to use for at least 2 months after the study vaccination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        In order to participate in this study, all subjects must not meet ANY of the exclusion&#xD;
        criteria described below:&#xD;
&#xD;
          -  Females of childbearing potential who are pregnant, lactating, or who have not adhered&#xD;
             to a specified set of contraceptive methods from at least 30 days prior to study entry&#xD;
             and who do not plan to do so until 2 months after the study vaccination&#xD;
&#xD;
          -  Progressive, unstable or uncontrolled clinical conditions&#xD;
&#xD;
          -  Hypersensitivity, including allergy, to any component of vaccines, medicinal products&#xD;
             or medical equipment whose use is foreseen in this study&#xD;
&#xD;
          -  History of any medical condition considered an AESI&#xD;
&#xD;
          -  Known history of Guillain Barré syndrome or another demyelinating disease such as&#xD;
             encephalomyelitis and transverse myelitis&#xD;
&#xD;
          -  Clinical conditions representing a contraindication to intramuscular vaccination and&#xD;
             blood draws&#xD;
&#xD;
          -  Abnormal function of the immune system resulting from:&#xD;
&#xD;
               1. Clinical conditions&#xD;
&#xD;
               2. Systemic administration of corticosteroids (PO/IV/IM) at a dose ≥20 mg/day of&#xD;
                  prednisone for more than 14 consecutive days within 90 days prior to informed&#xD;
                  consent. Topical, inhaled and intranasal corticosteroids are permitted.&#xD;
                  Intermittent use (one dose in 30 days) of intra-articular corticosteroids is also&#xD;
                  permitted&#xD;
&#xD;
               3. Administration of antineoplastic and immunomodulating agents or radiotherapy&#xD;
                  within 90 days prior to informed consent&#xD;
&#xD;
          -  Received immunoglobulins or any blood products within 180 days prior to informed&#xD;
             consent&#xD;
&#xD;
          -  Received an investigational or non-registered medicinal product within 30 days prior&#xD;
             to informed consent, or who are unwilling to refuse participation in another clinical&#xD;
             study at any time during the conduct of this study (note: concomitant participation in&#xD;
             an observational study not involving drugs, vaccines, or medical devices, is&#xD;
             acceptable)&#xD;
&#xD;
          -  Receipt of any influenza vaccine within 6 months prior to enrollment in this study, or&#xD;
             plan to receive influenza vaccine during the study period&#xD;
&#xD;
          -  Receipt of any (investigational or licensed) COVID-19 vaccine within 14 days&#xD;
             (non-replicating vaccines) or 28 days (replicating vaccines) prior to enrollment or&#xD;
             plan to receive any COVID-19 vaccine within 7 days from study vaccination&#xD;
&#xD;
          -  Receipt of any inactivated non-influenza vaccine within 14 days or live-attenuated&#xD;
             vaccine within 28 days prior to enrollment in this study or plan to receive any other&#xD;
             non-influenza vaccine within 28 days from study vaccination&#xD;
&#xD;
          -  Acute (severe) febrile illness&#xD;
&#xD;
          -  Any other clinical condition that, in the opinion of the investigator, might interfere&#xD;
             with the results of the study or pose additional risk to the subject due to&#xD;
             participation in the study&#xD;
&#xD;
          -  Study personnel or immediate family members or household member of study personnel&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Program Director</last_name>
    <role>Study Director</role>
    <affiliation>Seqirus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trial Disclosure Manager</last_name>
    <phone>+1 855 358 8966</phone>
    <email>seqirus.clinicaltrials@seqirus.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Use Central Contact</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>84013 Coastal Clinical Research, Inc.</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harry Studdard</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>84007 Alliance for Multispecialty Research</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85281</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corey Anderson</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>84005 JEM Research Institute</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larry Bush</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>84010 Headlands Research Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32819</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Galloway</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>84001 Meridian Clinical Research</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Bradley</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>84003 Meridian Clinical Research</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Ensz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>84006 Alliance for Multispecialty Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Ervin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>84009 Meridian Clnical Research</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay Meyer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>84002 Meridian Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Nebraska</state>
        <zip>68701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Harper</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>84004 Meridian Clinical Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandon Essink</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>84008 United Medical Associates</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Eder</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>84011 Meridian Clinical Research</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suchet Patel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>23302 Vee Family Doctors Centre</name>
      <address>
        <city>Paide</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Alt</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>23301 Innomedica OÜ - Outpatient</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaak Tälli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>23303 Al Mare Perearstikeskus OÜ</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaia Kiiroja</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>23304 Merelahe Family Doctors Centre</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riin Lanno</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>23306 Center for Clinical and Basic Research</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivo Valter</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>23305 Clinical Research Center - Vaccine Trials</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Airi Põder</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>27602 Klinische Forschung Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Schenkenberger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>27603 Emovis GmbH</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerstin Sturm</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>27608 Klinische Forschung Dresden GmbH</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Heymer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>27609 IKF Pneumologie GmbH &amp; Co. KG</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Kornmann</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>27611 Siteworks GmbH</name>
      <address>
        <city>Fulda</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joerg Simon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>27601 Klinische Forschung Hamburg GmbH</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uwe Desaga</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>27605 Clinical Research Hamburg GmbH</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Grigat</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>27604 Klinische Forschung Hannover-Mitte GmbH</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mareile Brunke</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>27607 Siteworks GmbH</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Albers</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>27606 SIBAmed GmbH &amp; Co KG</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Sigal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>27610 Studienzentrum Leitz Triderm</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Leitz</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 6, 2021</study_first_submitted>
  <study_first_submitted_qc>September 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza, Vaccine, MF59 adjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>SEQIRUS supports the release of anonymized subject-level and study-level data in compliance with regulatory requirements, including Clinical Documents which are part of the CTD modules submitted to regulatory agencies for public release.&#xD;
Summary results disclosure is either in document form (e.g., ICH E3 Clinical Study Report synopsis) or structured data form (such as summary results in ClinicalTrials.gov (United States) or eudract.ema.europa.eu (EU Clinical Trial Registry [EU CTR])).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>SEQIRUS discloses results from clinical studies within 12 months of last patient last visit (LPLV) unless otherwise mandated by local laws or regulations.</ipd_time_frame>
    <ipd_access_criteria>SEQIRUS will consider requests from qualified scientific and medical researchers to disclose protocols, anonymized subject-level data and study-level data when there is medical, scientific and/or public health interest to ensure the safe use of a Seqirus product licensed on or after 1 January 2014 in the United States (US) and/or the European Union (EU). This applies to Seqirus-sponsored interventional studies initiated after 27 September 2007 and ongoing as of 26 December 2007, that have been included as part of a US or EU submission package which received approval in US and EU on or after 1 January 2014 and have been accepted for publication.</ipd_access_criteria>
    <ipd_url>https://www.seqirus.us/partnering</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

